NASDAQ$VNDA

Vanda Pharmaceuticals Inc · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Briefing

Reported an 11% increase in total revenues compared to Q4 2019.

Vanda Pharmaceuticals reported Q4 2020 total revenues of $67.7 million, an 11% increase compared to Q4 2019. Income before taxes was $10.9 million in the fourth quarter of 2020 compared to $5.8 million in the fourth quarter of 2019.

  • Total net product sales from HETLIOZ® and Fanapt® were $67.7 million in Q4 2020, an 11% increase compared to Q4 2019.
  • HETLIOZ® net product sales were $44.2 million in Q4 2020, a 14% increase compared to Q4 2019.
  • Fanapt® net product sales were $23.5 million in Q4 2020, a 5% increase compared to Q4 2019.
  • Income before taxes was $10.9 million in Q4 2020 compared to $5.8 million in Q4 2019.

Headline financials

Total Revenue

$67.7M

Previous: $60.9M+11.0%
EPS (adj)

$0.15

Previous: $0.08+87.5%
Capital Expenditures

$966K

Previous: $68K+1320.6%
Free Cash Flow

$18.3M

Previous: $9.72M+88.6%
Net Income

$8.19M

Previous: $4.2M+95.0%
Operating Income

$10.5M

Previous: $4.24M+146.3%
Gross Profit

$61.2M

Previous: $54.7M+11.9%
Cash & Equivalents

$61M

Previous: $45.1M+35.4%
Total Assets

$533M

Previous: $484M+10.3%
Stock-Based Comp

$3.21M

Previous: $3.67M-12.4%

Revenue & EPS history

Vanda · Revenue · Quarterly

$67.7M

Q4 2020+11%vs Q4 2019
Beat estimate in 5 of 14 quarters(36%)
ActualEstimate

Revenue by segment

Vanda · $67.7M total across 2 segments · Q4 2020

  • HETLIOZ
    $44.2M+14.4%
  • Fanapt
    $23.5M+5.2%

Forward guidance

Vanda expects full year 2021 total revenues to be between $270 million and $300 million. Year-end 2021 Cash expected to be greater than $400 million.

Tailwinds

  • Full Year 2021 Total revenues expected to be between $270 to $300 million
  • HETLIOZ® net product sales expected to be between $180 to $200 million
  • Fanapt® net product sales expected to be between $90 to $100 million
  • Year-end 2021 Cash expected to be greater than $400 million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

-0.7%

Avg return

Earnings day

+0.0%

Avg return

5 days after

+1.9%

Avg return

30 days after

45%

29 / 65 earnings

Positive

+24.8%

Q2 2019

Best reaction

-23.7%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-10.5%-13.8%-19.1%
Q4 2025-17.6%-16.6%+18.6%
Q3 2025-0.9%-1.4%+21.4%
Q1 2025-3.9%-9.1%+5.3%
Q4 2024-6.0%-3.2%+6.0%
Q3 2024+4.8%+11.5%+1.0%
Q2 2024-3.4%-9.1%-9.4%
Q1 2024-8.6%-7.8%+11.7%
Q4 2023+9.1%+16.1%+3.8%
Q3 2023-23.7%-23.0%-15.1%
Q2 2023-8.8%-13.4%-14.3%
Q1 2023+7.0%+7.9%-5.6%
Q4 2022-4.6%-4.5%-18.0%
Q3 2022-4.8%-0.2%+2.5%
Q2 2022-1.2%+0.9%-0.5%
Q1 2022-6.2%-0.1%-0.8%
Q4 2021-5.0%-15.2%-14.5%
Q3 2021-11.8%-11.9%-21.2%
Q2 2021-7.4%-12.4%-10.5%
Q1 2021+5.1%+7.2%+8.6%
Q4 2020+20.5%+17.6%+15.5%
Q3 2020+3.8%+3.5%+17.2%
Q2 2020+6.2%+10.2%-5.3%
Q1 2020-4.4%+0.4%-2.5%
Q4 2019-3.7%-6.2%-20.5%
Q3 2019+7.6%+10.2%+29.4%
Q2 2019+24.8%+21.2%+11.4%
Q1 2019-3.1%+1.3%-9.9%
Q4 2018+9.3%+14.7%-0.7%
Q3 2018+16.7%+12.5%+37.2%
Q2 2018+4.1%+2.4%-7.3%
Q1 2018+10.6%+11.0%+25.1%
Q4 2017+6.6%+7.9%+4.7%
Q3 2017-16.8%-16.5%-11.7%
Q2 2017+7.1%+3.5%+11.3%
Q1 2017-0.3%-3.3%-8.0%
Q4 2016-0.7%+2.7%-1.7%
Q3 2016-8.4%-2.3%+4.7%
Q2 2016+2.7%+8.5%+36.9%
Q1 2016+3.9%
Q4 2015-0.6%
Q3 2015-9.5%
Q2 2015+8.3%
Q1 2015+7.2%
Q4 2014-12.7%
Q3 2014+8.3%
Q2 2014-11.3%
Q1 2014-20.2%
Q4 2013+7.2%
Q3 2013-3.3%
Q2 2013+4.0%
Q1 2013+7.6%
Q4 2012+0.8%
Q3 2012-6.2%
Q2 2012+1.0%
Q1 2012-0.4%
Q4 2011+6.5%
Q4 2009+6.5%
Q3 2011-2.2%
Q3 2010-2.2%
Q4 2010-10.9%
Q2 2011-10.9%
Q2 2010-10.9%
Q1 2011+1.7%
Q1 2010+7.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro